文献速递白血病造血干细胞移植与细胞治疗

老年同胞全合供者与年轻单倍体供者用于老年急性髓系白血病患者的比较

Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2025-01-01

该回顾性研究基于欧洲血液与骨髓移植学会注册数据库,纳入1247例(721例老年同胞全合供者、526例年轻单倍体供者)在首次完全缓解期接受移植的≥60岁急性髓系白血病患者。单倍体供者与较低复发、较高非复发死亡相关,多因素分析后总生存、无白血病生存和无GVHD无复发生存相似。

要点

  • 单倍体供者组复发发生率较低(P = .01),非复发死亡较高(P = .01)
  • 多因素分析显示两组总生存、无白血病生存和无GVHD无复发生存相似
  • 全体患者2年总生存、无白血病生存、无GVHD无复发生存分别为62.5%、56%、47%

核心结论

  • 在≥60岁首次完全缓解期接受移植的急性髓系白血病患者中,年轻单倍体供者较老年同胞全合供者复发更少但非复发死亡更高,总生存、无白血病生存和无GVHD无复发生存相似。

研究设计与样本

  • 回顾性研究,数据来自欧洲血液与骨髓移植学会注册数据库,共纳入1247例患者,其中同胞全合供者721例、单倍体供者526例。
  • 纳入标准为年龄≥60岁、在首次完全缓解期接受移植的急性髓系白血病患者,供者分别为年龄≥50岁的同胞全合供者或年龄≤40岁的单倍体供者。
  • 单倍体供者组接受移植后环磷酰胺预防移植物抗宿主病,同胞全合供者组接受体内T细胞去除。

主要发现

  • 单因素分析中,单倍体供者与较低的复发发生率相关(P = .01),与较高的非复发死亡相关(P = .01)。
  • 全体患者2年总生存概率为62.5%,无白血病生存概率为56%,无GVHD无复发生存概率为47%。
  • 多因素分析证实单倍体供者与较少复发但更多非复发死亡相关,总生存、无白血病生存和无GVHD无复发生存相似。

局限性

  • 原文为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selection of a suitable donor for allogeneic hematopoietic stem cell transplantation (allo-HCT) has mainly relied on HLA matching and, to date, a matched sibling donor (MSD) remains the first choice. However, patients with acute myeloid leukemia (AML) are older and therefore tend to have older siblings. Haploidentical donors (HIDs) are easily available, and offspring are younger than siblings. As donor age has been associated with worse outcomes, a younger HID might be a better choice than an older MSD for older patients with AML who receive transplantation in first complete remission (CR1). From the European Society for Blood and Marrow Transplantation registry database, we selected patients with AML aged ≥60 years who received transplantation in CR1, either from MSD aged ≥50 years or HID ≤40 years. HIDs received posttransplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis, and MSDs received in vivo T-cell depletion. A total of 1247 patients were identified, including 721 MSDs and 526 HIDs. In univariate analysis, HID was associated with lower relapse incidence (P = .01), higher nonrelapse mortality (NRM; P = .01). The 2-year probability of overall survival (OS), leukemia-free survival (LFS), and GVHD-free and relapse-free survival (GRFS) were 62.5%, 56%, and 47%, respectively for the all population. In multivariate analysis, we confirmed that HID was associated with less relapse but more NRM, which translated into similar OS, LFS, and GRFS. Based on this retrospective study, young HIDs led to less relapse but higher NRM than older MSDs after allo-HCT in an older population with AML in CR1.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Poiré X, Labopin M, Polge E, et al. Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia. Blood Adv. 2025. PMID: 40668660. doi:10.1182/bloodadvances.2024015582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。